Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 - Yahoo Finance
| VLA Stock | EUR 1.83 0.01 0.54% |
About 62% of Valneva SE's investor base is looking to short. The analysis of current outlook of investing in Valneva SE suggests that many traders are alarmed regarding Valneva SE's prospects. The current market sentiment, together with Valneva SE's historical and current headlines, can help investors time the market. In addition, many technical investors use Valneva SE stock news signals to limit their universe of possible portfolio assets.
Valneva |
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 Yahoo Finance
Read at news.google.com
 |
Valneva SE Fundamental Analysis
We analyze Valneva SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Valneva SE using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Valneva SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Valneva SE is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Valneva SE Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Valneva SE stock to make a market-neutral strategy. Peer analysis of Valneva SE could also be used in its relative valuation, which is a method of valuing Valneva SE by comparing valuation metrics with similar companies.
Peers
Valneva SE Related Equities
| IPH | Innate Pharma | 22.58 | ||||
| VALN | Valneva SE | 0.76 | ||||
| GNFT | Genfit | 1.40 | ||||
| NANO | Nanobiotix | 2.13 | ||||
| DBV | DBV Technologies | 5.71 |
Complementary Tools for Valneva Stock analysis
When running Valneva SE's price analysis, check to measure Valneva SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Valneva SE is operating at the current time. Most of Valneva SE's value examination focuses on studying past and present price action to predict the probability of Valneva SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Valneva SE's price. Additionally, you may evaluate how the addition of Valneva SE to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |